The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

被引：1
|
作者：
Gier, Chad [1 ]
Gilchrist, Ian [1 ]
Fordham, Matthew [1 ]
Riordan, Luke [1 ]
Milchan, Ella [2 ]
Patel, Nidhi [2 ]
Mohedi, Azad [2 ]
Choudhury, Sahana [1 ]
Kits, Tara [1 ]
Cohen, Regina [1 ]
Doughtery, Joseph [1 ]
Reilly, John P. [1 ]
Kalogeropoulos, Andreas [1 ]
Rahman, Tahmid [1 ]
Chen, On [1 ]
机构：
[1] Stony Brook Univ Hosp, Stony Brook Heart Inst, Stony Brook, NY 11794 USA
[2] Stony Brook Renaissance Sch Med, Stony Brook, NY USA
来源：
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2024年 / 11卷
关键词：
hyperlipidemia; quality improvement; ASCVD; lipid lower medications; LDL-Cholesterol; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; BEMPEDOIC ACID; EFFICACY; SAFETY;
D O I：
10.3389/fcvm.2024.1284562
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.
引用
收藏
页数：6
相关论文
共 31 条
  • [21] Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
    Teramoto, Tamio
    Kondo, Akira
    Kiyosue, Arihiro
    Harada-Shiba, Mariko
    Ishigaki, Yasushi
    Tobita, Kimimasa
    Kawabata, Yumiko
    Ozaki, Asuka
    Baccara-Dinet, Marie T.
    Sata, Masataka
    LIPIDS IN HEALTH AND DISEASE, 2017, 16
  • [22] Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON
    Teramoto, Tamio
    Kiyosue, Arihiro
    Ishigaki, Yasushi
    Harada-Shiba, Mariko
    Kawabata, Yumiko
    Ozaki, Asuka
    Baccara-Dinet, Marie T.
    Sata, Masataka
    JOURNAL OF CARDIOLOGY, 2019, 73 (3-4) : 218 - 227
  • [23] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Julius L. Katzmann
    Francesc Sorio-Vilela
    Eugen Dornstauder
    Uwe Fraas
    Timo Smieszek
    Sofia Zappacosta
    Ulrich Laufs
    Clinical Research in Cardiology, 2022, 111 : 243 - 252
  • [24] A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography
    Al'Aref, Subhi J.
    Su, Amanda
    Gransar, Heidi
    van Rosendael, Alexander R.
    Rizvi, Asim
    Berman, Daniel S.
    Canister, Tracy Q.
    DeLago, Augustin
    Hadamitzky, Martin
    Hausleiter, Joerg
    Al-Mallah, Mouaz H.
    Budof, Matthew J.
    Kaufmann, Philipp A.
    Raff, Gilbert L.
    Chinnaiyan, Kavitha
    Cademartiri, Filippo
    Maffei, Erica
    Villines, Todd C.
    Kim, Yong-Jin
    Leipsic, Jonathon
    Feuchtner, Gudrun
    Pontone, Gianluca
    Andreini, Daniele
    Marques, Hugo
    Goncalves, Pedro de Araujo
    Rubinshtein, Ronen
    Achenbach, Stephan
    Chang, Hyuk-Jae
    Chow, Benjamin J. W.
    Cury, Ricardo
    Lu, Yao
    Bax, Jeroen J.
    Jones, Erica C.
    Pena, Jessica M.
    Shaw, Leslee J.
    Min, James K.
    Lin, Fay Y.
    JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY, 2019, 13 (02) : 99 - 104
  • [25] A comparative study on serum lipid levels in patients with thyroid dysfunction: a single-center experience in Ethiopia
    Kebamo, Tamirat Ersino
    Tantu, Abinet
    Solomon, Yenealem
    Walano, Getachew Alemu
    BMC ENDOCRINE DISORDERS, 2025, 25 (01)
  • [26] Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
    Chaiyasothi, Thanaputt
    Nathisuwan, Surakit
    Dilokthornsakul, Piyameth
    Vathesatogkit, Prin
    Thakkinstian, Ammarin
    Reid, Christopher
    Wongcharoen, Wanwarang
    Chaiyakunapruk, Nathorn
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
    Sasidharan, Akhil
    Bagepally, Bhavani Shankara
    Kumar, S. Sajith
    Jagadeesh, Kayala Venkata
    Natarajan, Meenakumari
    PLOS ONE, 2022, 17 (06):
  • [28] Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines
    Moghnieh, Rima
    El-Rajab, Nabila
    Abdallah, Dania Issam
    Fawaz, Ismail
    Mugharbil, Anas
    Jisr, Tamima
    Ibrahim, Ahmad
    FRONTIERS IN MEDICINE, 2016, 2
  • [29] Aggressive lipid-lowering treatment in Managed Care after Acute Myocardial Infarction (MC-AMI) patients: Results better but still not satisfactory. A single-center prospective analysis
    Kulach, Andrzej
    Wieczorek, Piotr
    Urbanczyk-Swic, Dagmara
    Turski, Maciej
    Wita, Michal
    Grabarczyk, Malgorzata
    Wita, Krystian
    KARDIOLOGIA POLSKA, 2024, 82 (02) : 203 - 205
  • [30] Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
    Mohring, Christian
    Graffe, Freddy Jose Frontado
    Bartels, Alexandra
    Sadeghlar, Farsaneh
    Zhou, Taotao
    Mahn, Robert
    Marinova, Milka
    Feldmann, Georg
    Brossart, Peter
    Glowka, Tim R.
    Kalff, Jorg C.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (01) : 352 - 365
1234